| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.05 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.089 | 0.05 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.06 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.091 | 0.06 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.096 | 0.06 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.06 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.082 | 0.06 |